An orally administered quinolinium molecule mitigates neuropathology of Alzheimer’s disease through modulation of mitochondrial dysfunction and neuroinflammation
Brain Research · 2025
DOI: 10.1016/j.brainres.2025.149804 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain Research, 2025. Verfasst von Junqiu He und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Mitochondria, Quinolinium Compounds, Neuroinflammatory Diseases. Die Arbeit nennt 64 Literaturangaben. Gefördert von: Universidade de Macau, Fund for the Development of Science and Technology.
Themen: Demenz
Abstract (Originalsprache)
Development of therapeutic options for Alzheimer's disease (AD) faces severe challenges. Only a few new anti-amyloid drugs based on monoclonal antibodies have been approved in recent years. Although the diversity of etiology and complexity of pathology make AD difficult to cure, these offer various molecular targets amenable for pharmaceutical interventions and disease modulation. In this study, we report an orally bioavailable quinolinium small molecule inhibitor, 88, to modulate neuropathologic changes in triple transgenic AD (3 × Tg-AD) mice. We have shown that 88 exhibited decent cerebral exposure, as compared with the forerunner quaternary isoquinolinium compound, 9Q, that we previously developed. In vivo studies revealed that 88 significantly mitigated cognitive deficits in 3 × Tg AD mice and decreased the amyloid burden as well as tau tangles in the hippocampus. Our data indicated that 88 treatments ameliorated the neuroinflammation via inhibiting glial activation and reducing cytokines IL-1β and IL-6. In vitro studies showed that 88 stabilized mitochondria membrane potential (MMP), decreased ROS generation, recovered respiratory function and ATP production in β-amyloid (Aβ)-induced PC12 cell model, suggesting mitigation of mitochondrial dysfunction. Such restored mitochondrial activity reduced the release of cytochrome c, which helped to prevent neuronal apoptosis both in vitro and in vivo. Our findings suggested that 88 could be useful in modulating AD, while the restoration of mitochondria functions and amelioration of neuroinflammation could be promising avenues for disease modulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China.
- Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China. Electronic address: kintam@um.edu.mo.
Förderung
- Universidade de Macau
- Fund for the Development of Science and Technology
Zitieren
APA
He, J., Ran, M., & Tam, K. Y. (2025). An orally administered quinolinium molecule mitigates neuropathology of Alzheimer’s disease through modulation of mitochondrial dysfunction and neuroinflammation. Brain Research. https://doi.org/10.1016/j.brainres.2025.149804
Vancouver
He J, Ran M, Tam KY. An orally administered quinolinium molecule mitigates neuropathology of Alzheimer’s disease through modulation of mitochondrial dysfunction and neuroinflammation. Brain Research. 2025. doi:10.1016/j.brainres.2025.149804
BibTeX
@article{He2025,
author = {He, Junqiu and Ran, Maoxin and Tam, Kin Yip},
title = {An orally administered quinolinium molecule mitigates neuropathology of Alzheimer’s disease through modulation of mitochondrial dysfunction and neuroinflammation},
journal = {Brain Research},
year = {2025},
doi = {10.1016/j.brainres.2025.149804}
}
EUVIMED